ArticleBMC immunology2024

Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy.

Xingyi Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.